In February 2004, the U.S. Food and Drug Administration (FDA) approved<unk>  for treatment of malignant pleural mesothelioma, a type of tumor of the mesothelium, the thin layer of tissue that covers many of the internal organs, in combination with cisplatin for patients whose disease is either unresectable or who are not otherwise candidates for curative surgery. In September 2008, the FDA granted approval as a first-line treatment, in combination with cisplatin, against locally advanced and metastatic non-small cell lung cancer (NSCLC) in patients with non-squamous histology. Carboplatin<unk>  is also recommended in combination with carboplatin and pembrolizumab for the first-line treatment of advanced non-small cell lung cancer. However, the relative efficacy or toxicity of<unk> -cisplatin versus<unk> -carboplatin has not been established beyond what is generally thought about cisplatin or carboplatin doublet drug therapy. Supplementation Patients are recommended to take folic acid and vitamin B12 supplement even if levels are normal when they are on<unk>  therapy. (In clinical trials for mesothelioma, folic acid and B12 supplementation reduced the frequency of adverse events.) It is also recommended for patients to be on a glucocorticoid (e.g. dexamethasone) on the day prior, day of, and day after<unk>  infusion to avoid skin rashes.
Pemetrexed
Nilotinib
Vincristine
Normustine
Gemcitabine
Epirubicin
Ifosfamide
Vinorelbine